Here are three takeaways:
1. The Warning Letter regarded Zimmer Biomet’s Zhejiang, China manufacturing facility.
2. During a January 2015 onsite inspection, the FDA found manufacturing practice issues.
3. Zimmer Biomet President and CEO noted the company “will continue to take the necessary actions to demonstrate our commitment to quality excellence, patient safety and regulatory compliance.”
More articles on devices:
Global spinal fusion devices market valued at $7.435M by 2022: 7 highlights
6 trends in the personalized orthopedic market
Amedica reports preliminary 2016 revenue of $15.2M — 10 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
